UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

FORM 144/A

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

#### 144/A: Filer Information

Filer CIK 0001564926 Filer CCC XXXXXXXX

Previous Accession Number Of The Filing 0000874015-24-000088

Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name Phone

E-Mail Address

### 144/A: Issuer Information

Name of Issuer IONIS PHARMACEUTICALS INC

SEC File Number 000-19125

2855 GAZELLE COURT

**CARLSBAD** Address of Issuer

**CALIFORNIA** 

92010

Phone 7609319200

O'NEIL PATRICK R. Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Officer Relationship to Issuer

### 144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	1995	99099.31	143472119	02/02/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

### 144/A: Securities To Be Sold

Title of the	Date you	Nature of	Name of Person	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	from Whom	this	Donor	Securities	Payment	Payment *

	Transaction	Acquired	a Acquired Gift?	Acquired	
Common Stock 02/01/2024	PSUs grantedunder the 2011Equity IncentivePlan	Ionis Pharmaceuticals, Inc.		1995	02/01/2024 Services rendered

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	<b>Gross Proceeds</b>
Insight Securities, Inc. 600 Central STE 293 HIghland Park IL 60035	Common Stock	12/26/2023	20825	1072487.50
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/17/2024	7645	385437.96
Insight Securities, Inc. 600 Central STE 293 HIghland Park IL 60035	Common Stock	01/25/2024	6450	337787.50

# 144/A: Remarks and Signature

Remarks Updated number of shares sold.

Date of Notice 09/04/2024

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Patrick R. O'Neil

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)